Fate Therapeutics, Inc. rose 3.57% in after-hours trading, with the company announcing that it granted non-qualified stock options to a newly-hired non-executive employee to purchase 30,000 shares of the company’s common stock at an exercise price per share of $1.12. This news event is positive for the stock as it indicates the company's confidence in its future growth and its ability to attract and retain talent.
Comments
No comments yet